• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Jaguar Health Inc (NQ: JAGX )

    1.119 +0.009 (+0.77%)
    Streaming Delayed Price Updated: 10:17 AM EDT, Oct 28, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 21,677
    Open 1.120
    Bid (Size) 1.110 (35)
    Ask (Size) 1.120 (15)
    Prev. Close 1.110
    Today's Range 1.110 - 1.130
    52wk Range 0.9501 - 30.86
    Shares Outstanding 171,350,166
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
    Via ACCESSWIRE
    Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Via ACCESSWIRE

    Performance

    YTD
    -87.67%
    -87.67%
    1 Month
    -6.78%
    -6.78%
    3 Month
    -10.51%
    -10.51%
    6 Month
    -91.04%
    -91.04%
    1 Year
    -94.52%
    -94.52%

    More News

    Read More
    Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
    Via ACCESSWIRE
    Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial
    Via ACCESSWIRE
    Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
    Via ACCESSWIRE
    New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company’s Near-Term Commercial & Development Milestones
    Via ACCESSWIRE
    Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
    Via ACCESSWIRE
    Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
    Via ACCESSWIRE
    Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and
    Via ACCESSWIRE
    Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
    Via ACCESSWIRE
    Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch
    Via ACCESSWIRE
    Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference
    Via ACCESSWIRE
    Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care
    Via ACCESSWIRE
    Why Jaguar Health (JAGX) Stock Is Down 15%
    Via Benzinga
    Jaguar Health Reports Second Quarter 2024 Financial Results
    Via ACCESSWIRE
    Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
    Via ACCESSWIRE
    Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference
    Via ACCESSWIRE
    Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
    Via ACCESSWIRE
    Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
    Via ACCESSWIRE
    JAGX Stock Earnings: Jaguar Health Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
    Via ACCESSWIRE
    Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningful
    Via ACCESSWIRE
    Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
    Via ACCESSWIRE
    Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
    Via ACCESSWIRE
    Gold Moves Higher; Coca-Cola Increases FY24 Forecast
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.